Xtant Medical Holdings, Inc. (XTNT) fundamentals score
access to IDNs across the United States for both biologics and spine hardware systems. While its focus is the United States market, we
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NYSE
Overall: 3.9 out of 10, Weak long-term fundamentals
- Growth: 2.2/10
- Profitability: 2.9/10
- Financial health: 2.7/10
- Earnings quality: 9.3/10
- Valuation: 4.3/10
Scores are calculated from Xtant Medical Holdings, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10